Trojan horses encapsulated by a TRODELVYᵀᴹ cell membrane in a green, cellular environment.

DOSING AND ADMINISTRATION

START TRODELVY AT 10 MG/KG

The recommended dose of TRODELVY is 10 mg/kg intravenously on Days 1 and 8 of 21-day treatment cycles1

  • Continue treatment until disease progression or intolerance to therapy
  • Do not administer TRODELVY at doses greater than 10 mg/kg
  • Administer TRODELVY as an intravenous infusion only. Do not administer as an intravenous push or bolus
  • Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite, SN-38

21-day treatment cycles1

Chart showing the TRODELVY® (sacituzumab govitecan-hziy) administration cycle

First infusion1

  • Administer infusion over 3 hours
  • Observe patients during the infusion and for at least 30 minutes following the initial dose for signs or symptoms of infusion-related reactions

Subsequent infusions1

  • Administer infusion over 1 to 2 hours if prior infusions were tolerated
  • Observe patients during the infusion and for at least 30 minutes after the infusion

Prior to each dose of TRODELVY1

  • Premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting (CINV) is recommended
  • Premedicate with antipyretics, H1 and H2 blockers prior to infusion, and corticosteroids may be used for patients who had prior infusion reactions
  • Premedicate with a 2- or 3-drug combination regimen (eg, dexamethasone with either a 5-HT3 receptor antagonist or an NK1 receptor antagonist, as well as other drugs as indicated)
  • Medication to treat infusion-related reactions, as well as emergency equipment, should be available for immediate use

AFTER INITIATION ON STARTING DOSE, DOSES CAN BE MODIFIED AS NEEDED TO HELP MANAGE ADVERSE REACTIONS

Withhold or discontinue TRODELVY to manage adverse reactions as described in table below

Dose modifications for adverse reactions1

  • Do not re-escalate the TRODELVY dose after a dose reduction for adverse reactions has been made1
  • Slow or interrupt the infusion rate of TRODELVY if the patient develops an infusion-related reaction1
  • Permanently discontinue TRODELVY for life-threatening infusion-related reactions1
TRODELVY® (sacituzumab govitecan-hziy) Reconstitution Guide

Reconstitution Guide

Get step-by-step instructions on how to reconstitute and administer TRODELVY

Reference: 1. TRODELVY [package insert]. Foster City, CA: Gilead Sciences, Inc.; April 2021.